Cite
Sundström J, Kristófi R, Östlund O, et al. A registry-based randomised trial comparing an SGLT2 inhibitor and metformin as standard treatment of early stage type 2 diabetes (SMARTEST): Rationale, design and protocol. J Diabetes Complications. 2021;35(10):107996doi: 10.1016/j.jdiacomp.2021.107996.
Sundström, J., Kristófi, R., Östlund, O., Bennet, L., Eliasson, B., Jansson, S., Leksell, J., Almby, K., Lundqvist, M., Eriksson, J. W. (2021). A registry-based randomised trial comparing an SGLT2 inhibitor and metformin as standard treatment of early stage type 2 diabetes (SMARTEST): Rationale, design and protocol. Journal of diabetes and its complications, 35(10), 107996. https://doi.org/10.1016/j.jdiacomp.2021.107996
Sundström, Johan, et al. "A registry-based randomised trial comparing an SGLT2 inhibitor and metformin as standard treatment of early stage type 2 diabetes (SMARTEST): Rationale, design and protocol." Journal of diabetes and its complications vol. 35,10 (2021): 107996. doi: https://doi.org/10.1016/j.jdiacomp.2021.107996
Sundström J, Kristófi R, Östlund O, Bennet L, Eliasson B, Jansson S, Leksell J, Almby K, Lundqvist M, Eriksson JW. A registry-based randomised trial comparing an SGLT2 inhibitor and metformin as standard treatment of early stage type 2 diabetes (SMARTEST): Rationale, design and protocol. J Diabetes Complications. 2021 Oct;35(10):107996. doi: 10.1016/j.jdiacomp.2021.107996. Epub 2021 Jul 21. PMID: 34389234.
Copy
Download .nbib